

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015, India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

December 26, 2014

**Bombay Stock Exchange Limited**

1<sup>st</sup> Floor, P.J. Towers  
Dalal Street  
MUMBAI – 400 001

Kind Attn.: Mr. Sanjay Golecha  
Mr. Gopalkrishnan

**National Stock Exchange of India Ltd.**

Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block  
Bandra- Kurla Complex  
Bandra – (East)  
Mumbai – 400 051

Kind Attn.: Famroze Pochara  
Asst. Vice President

**Ahmedabad Stock Exchange Limited**

Kamdhenu Complex  
Opp. Sahajanand College  
Panjra Pole,  
Ahmedabad – 380 015

**Re.:** Abstract of interaction with press.

Dear Sir / Madam


We bring to your notice that our Chairman and Managing Director Mr. Pankaj R. Patel had an interaction with 'Times of India' during which he was asked about the other treatment options of Lipaglyn (Saroglitazar) which was introduced in 2013. During the course of the interaction he spoke about the initiation of Phase-III clinical trials to study the effect of Saroglitazar in adult nonalcoholic seatohepatitis (NASH) patients. NASH is a liver disease in which fat accumulates in the liver. Obesity, insulin resistance, diabetes and lipid disorders progresses to cause a lethal NASH situation.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

FOR CADILA HEALTHCARE LIMITED

  
UPEN H. SHAH

COMPANY SECRETARY

For